Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous Bone Marrow Mononuclear Cells · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Autologous Bone Marrow Mononuclear Cells | EXPERIMENTAL | Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells |
| Name | Type | Description |
|---|---|---|
| Autologous Bone Marrow Mononuclear Cells | PROCEDURE | Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow. |
Inclusion Criteria: * Diabetic patients under treatment (type I or II) * Critical limb ischemia (rest pain and/or non-healing ischemic ulcers lasting more than 4 weeks, and/or Ankle-Brachial Index \< 0,8) * Not suitable to be revascularized (surgical and interventional consensus) Exclusion Criteri...
Autologous Bone Marrow Mononuclear Cells is an investigational cell therapy being studied for peripheral vascular diseases, specifically in diabetic patients with critical limb ischemia. It is currently in Phase 1 clinical development and is not approved by the FDA.
Autologous Bone Marrow Mononuclear Cells is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker DSGN. The therapy is in Phase 1 clinical trials for peripheral vascular diseases.
Autologous Bone Marrow Mononuclear Cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the therapy remains under investigation for peripheral vascular diseases.
Autologous Bone Marrow Mononuclear Cells has one completed clinical trial, NCT00872326, titled 'Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia.' This Phase 1 study enrolled 20 participants in Spain and was not randomized or blinded.
Yes, Autologous Bone Marrow Mononuclear Cells is also referred to as autologous bone marrow derived mononuclear cells. The clinical trial NCT00872326 uses this alternative name in its title, confirming they refer to the same investigational cell therapy.